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ABSTRACT 
 
 Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer 
worldwide and despite advancements in traditional therapies, the survival rate of ~40% 
remains unchanged, thus highlighting the need for novel treatments in HNSCC. High 
throughput robotic screening of a panel of HNSCC cell lines was carried out against 1,505 
compounds, where drug activity was measured using metabolic agent alamarBlue and 
quantified by percent activity. Initial screening found that the majority of active compounds 
could be grouped based upon their cellular target(s) and/or function including: cell cycle 
regulation, cytoskeleton disruption, and DNA topoisomerase function. Potency was 
confirmed with dose response curves for 23 hit compounds and ER27319 maleate and 
NSC146109 hydrochloride were selected for further investigation. ER27319 maleate was 
observed to control tumour growth in vivo. This systematic high throughput screen of large 
panels of drugs identified a multitude of potentially effective agents for the treatment of 
HNSCC.  
 
 
Keywords: HNSCC, HPV, high throughput, drug screening, targeted therapy, precision 
medicine, cell lines, spleen tyrosine kinase 
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1 INTRODUCTION 
  
 Cancer is the leading cause of death worldwide, accounting for approximately 8.2 
million deaths in 2012 [1]. According to the World Health Organization’s International 
Agency for Research on Cancer, the number of new cancer cases is expected to rise about 
70% over the next two decades. This predicted increase is based on both the growing 
elderly population worldwide as well as the continued exposure to major risk factors of 
cancer such as tobacco and alcohol use, unhealthy diet and physical inactivity [1]. 
Tobacco use continues to be the most important risk factor for cancer and is responsible 
for about 20% of global cancer deaths annually [1]. 
 Head and neck cancers comprise a group of malignancies that arise in many 
different areas of the head and neck region including: the oral cavity, larynx, pharynx, 
paranasal sinuses and nasal cavity as well as the salivary glands. Head and neck cancers 
are currently the sixth most common cancer by incidence worldwide [2]. Tobacco and 
alcohol use remain the two most important risk factors for head and neck cancers, 
however, infection with human papillomavirus (HPV) has recently been recognized as an 
important risk factor for some head and neck cancers, particularly oropharyngeal cancers 
(OPC) involving the tonsils and base of tongue [3, 4, 5]. Over the next decade, HPV-
positive OPCs are predicted to exceed the annual number of cervical cancer cases in the 
United States [6]. This rise in OPCs has been observed by many different countries 
worldwide, and presents a looming health concern for decades to come. 
 Currently, treatment of head and neck cancer is limited to chemotherapy, 
radiation therapy and/or surgery. Unfortunately, despite advances in each of these 
2 
 
treatment modalities, there has been no marked improvement in overall patient survival 
thus highlighting the need for new therapeutic options. 
 This thesis focuses on identifying highly active agents that can suppress the 
growth of head and neck cancer cell lines with the goal of identifying novel drug 
compounds and cellular targets for the improved treatment of head and neck cancers.  
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2 LITERATURE REVIEW 
 
2.1 Cancer 
 
 Cancer is a complex disease in which cells of a specific tissue fail to respond to 
signals that regulate cellular survival, proliferation, differentiation and death. As a result, 
these non-responsive cells can accumulate and cause local disease [7]. Cancer cells have 
been characterized as having six hallmark traits including: resisting cell death, sustaining 
proliferative signaling, evading growth suppressors, activating invasion and metastasis, 
enabling replicative immortality and inducing angiogenesis (Figure 1) [7]. More recently, 
research has suggested that there are two additional hallmarks of cancer that are 
emerging, with one involving reprogramming of cellular metabolism to support cancer 
cell proliferation and the other which enables cells to evade destruction by the immune 
system. In addition, inflammation and genome instability have been found to be 
important factors that help enable tumour progression [7]. 
 Cancer has long been understood to be a process of clonal evolution in which 
rounds of clonal selection of distinct cancer cells within a tumour give rise to extremely 
heterogeneous tumours [8]. This process of clonal expansion and selection leads to 
genetic diversification within a tumour. For example, as cancer cells rapidly divide, 
external pressures such as cytotoxic chemotherapy often select for clonal populations that 
are highly mutated and/or resistant to treatment thus resulting in treatment-resistant 
tumour cells with increased mutation rates and heterogeneity [8]. It has been observed  
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Figure 1. The hallmarks of cancer. 
 
This schematic includes the six hallmark features that enable cancer cell growth and 
metastases. These hallmarks help provide a solid foundation for our current 
understanding of basic cancer biology. Extensive research has been performed on each of 
these six hallmarks to help improve our understanding of these processes as well as the 
overall development and progression of a tumour. Addtionally, recent research has 
suggested that two additional cancer hallmarks are emerging with one involving 
reprogramming of cellular metabolism and the other which enables cells to evade 
immunological destruction (adapted from Hanahan and Weinberg, 2011). 
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that there is extensive genetic and phenotypic diversity both between tumours 
(intertumour heterogeneity) and within an individual tumour (intratumour heterogeneity) 
[9]. One of the major causes of both intertumour and intratumour heterogeneity in cancer 
is genomic instability in these uncontrolled cancer cells, which results in increased 
mutation rates and gene expression [9]. Heterogeneity in cancer has a tremendous effect 
on treatment decisions and must be considered when attempting to optimize cancer 
therapy and improve patient outcomes [9, 10]. 
 There are over 200 different types of cancer that have been identified to date [11]. 
In 2014, over 190,000 new cases of cancer were diagnosed in Canada and of these, 
approximately 76,000 (40%) resulted in death [12]. In order to help improve these 
statistics, it is essential to remember that each individual cancer is unique and tumour 
heterogeneity needs to be taken into consideration for improved cancer screening, 
diagnosis, and prognosis as well as treatment decisions [8]. 
 
2.2 Head and Neck Squamous Cell Carcinoma 
  
 Head and neck cancers are the sixth most common cancer by incidence 
worldwide, affecting approximately 600,000 new individuals each year [2]. 
Unfortunately, the mortality rate for advanced head and neck cancers remains at 
approximately 40% with no significant improvement observed in the last few decades 
[2]. Approximately 90% of head and neck cancers are squamous cell carcinoma, 
originating in the epithelium of the upper aerodigestive tract [13]. Head and neck 
squamous cell carcinoma (HNSCC) includes malignancies arising in many different sites  
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Figure 2. Anatomy of the head and neck. 
 
Head and neck cancers have a wide variety of primary site locations including the nasal 
and oral cavities, larynx, paranasal sinuses, tongue, epithelium, salivary glands and the 
pharynx (throat) which consists of three parts: the nasopharynx, oropharynx, and 
hypopharynx (adapted from http://www.cancer.gov/types/head-and-neck). 
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within the head and neck region including: the oral cavity, paranasal sinuses, nasal cavity, 
tongue, lips, tonsils, salivary glands, pharynx, and larynx (Figure 2) [13].  
 Historically, HNSCC has long been associated with heavy tobacco use and 
alcohol consumption, typically presenting in elderly males [13]. In Canada, the 
government has invested millions of dollars into lowering the incidence of smoking over 
the past few decades. Fortunately, these initiatives have proven successful with the 
prevalence of smoking decreasing over 30% from 1965 (49.5%) to 2009 (18%) in both 
male and females ≥15 years of age (Figure 3) [14]. With these declines in smoking, the 
overall incidence of HNSCC has also been found to be decreasing. However, a subset of 
HNSCC cases involving the oropharynx has risen dramatically (Figure 4) [5, 15]. This 
rise in OPC has been shown to be caused by oral infection with HPV [5, 15]. 
 
2.3 HPV-positive HNSCC 
 
 Despite the overall reduction in HNSCC cases caused by tobacco use and alcohol 
consumption, primarily attributed to government efforts to decrease smoking, a subset of 
HNSCC cases involving the oropharynx have been found to be increasing in incidence 
(Figure 4) [5, 15]. The cause of this increase is due to sexually transmitted oral infection 
with HPV [15]. Unlike HPV-positive cervical cancers which are typically caused by 
infection with high-risk HPV types including HPV type 16 and 18; HPV-positive OPC 
are almost always caused by infection with HPV type 16 (90%+ of cases) [15]. The 
reasons for this increase in oral HPV infection remain unclear; however, it is  
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Figure 3. Smoking Declines in Canada. 
 
This graph represents the percentage of Canadians who smoke, aged >15 years, on either 
a daily or occasional basis, based on surveys collected by the federal government from 
1965 to 2009 (adapted from Physicians for a smoke-free Canada, 2012). 
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Figure 4. Frequency of HPV-positive and HPV-negative HNSCC cases. 
 
Proportion of tonsillar carcinomas positive and negative for HPV during three sequential 
time intervals from patient samples obtained at the London Health Science Centre in 
London, Ontario, Canada, from 1993-2011. A rise in HPV-positive tonsillar HNSCC 
cases was observed beginning in 2000 (adapted from Nichols et al., 2013). 
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hypothesized that changes in sexual practices, specifically oral-genital contact, may be an 
important factor [15].  
 This rise in OPC has been observed in the United States [17], Australia, Japan and 
many other economically developed countries worldwide [18] and was also recently 
shown by our laboratory to be occurring in Canada [5]. Approximately 25% of tonsillar 
cancer cases in 1993 tested positive for HPV in a cohort of patients from Southwestern, 
Ontario, Canada, as compared to the 62% of cases that were found to be HPV-positive in 
2011 (Figure 4) [5].   
 Demographically, HPV-positive patients have been found to differ quite 
substantially from the historical HPV-negative HNSCC patient seen in clinics who had a 
long history of tobacco exposure and alcohol consumption. Patients with HPV-positive 
tumours tend to be younger, healthier and have no history of smoking [19]. In addition, 
these patients have a tendency to be more highly educated, affluent, and have had a 
higher number of lifetime oral sex partners than HPV-negative patients [19].  
Despite the increasing number of HPV-positive cases occurring worldwide, it has 
been observed that patients with HPV-positive HNSCC have a better five-year overall 
and disease-free survival prognoses than HPV-negative patients (Figure 5) [5]. Since 
these patients are younger and healthier than patients with HPV-negative HNSCC and are 
increasing in frequency, it is crucial that emerging treatments for HNSCC have maximum 
benefits with minimal toxicity since these patients are more likely to be living with the 
consequences of their treatment for years, or even decades to come. 
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Figure 5. Overall survival for HPV-positive and HPV-negative HNSCC patients. 
 
A survival analysis was performed using the Kaplan–Meier estimate comparing overall 
and disease-free survivals of 95 patients in Southwestern, Ontario, Canada with either 
HPV-positive versus HPV-negative oropharyngeal HNSCC tumours. HPV-positive 
patients were found to have significantly improved five-year overall and disease-free 
survivals as compared to patients with HPV-negative tumours (Nichols et al., 2013). 
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2.4 Mutational Landscape of HNSCC 
 
 In January 2015, the Cancer Genome Atlas (TCGA) Network completed a 
comprehensive genetic characterization of HNSCC, which included a multi-platform 
analysis of 279 tumour-normal pairs (HPV-negative n=243, HPV-positive n=36) 
including exome sequencing, copy number analysis, methylation expression arrays, and 
RNA sequencing [20].  Genes previously known to be altered in HNSCC were confirmed 
including: TP53, CDKN2A, PTEN, PIK3CA, and HRAS (Table 1) [20]. In addition, 
alterations in genes not previously associated with HNSCC were also identified such as 
loss of TRAF3 and amplification of E2F1 in HPV-positive tumours [20]. Finally, copy 
number analysis using single-nucleotide polymorphism arrays detected previously known 
CCND1 amplifications, CDKN2A deletions and more infrequent MYC, EGFR, ERBB2, 
and CCNE1 amplifications [20]. 
In addition to identifying genetic alterations that were previously associated with 
HNSCC as well as novel genetic variations, the mutational landscapes between HPV-
positive and HPV-negative HNSCC tumours were found to differ immensely (Table 1) 
[20, 21, 22]. This finding is consistent with the differing etiologies of HPV-positive and 
HPV-negative HNSCC tumours. In HPV-negative malignancies, the disease is most often 
caused by long-term exposure to tobacco as well as heavy alcohol consumption. Such a 
cancer almost always has a mutated TP53 gene as well as an extensive number of 
additional mutated genes including inactivated CDKN2A (Table 1) and amplification of 
3q26/28 and 11q13/22 [20]. In contrast, HPV-positive HNSCC cases arise from the  
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Table 1. Candidate therapeutic targets and driver oncogenic events in HNSCC. 
 
  
Frequency of 
alteration events 
in HPV- (%) 
Frequency of 
alteration events  
in HPV+ (%) 
R
ec
ep
to
r 
ty
ro
si
n
e 
k
in
as
es
 EGFR 15 6 
FGFR1 10 0 
ERBB2 5 3 
IGF1R 4 0 
EPHA2 4 3 
DDR2 3 6 
FGFR2 2 0 
FGFR3 2 11 
MET 2 0 
O
n
co
g
en
es
 
CCND1 31 3 
MYC 14 3 
HRAS 5 0 
P
I3
K
 PIK3CA 34 56 
PTEN 12 6 
PIK3R1 1 3 
T
S
G
1
 TP53 84 0 
CDKN2A 58 3 
NF1 3 0 
 
1TSG, tumour suppressor gene 
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oncogenic action of viral oncoproteins, E6 and E7, which target essential, wild-type 
tumour suppressors p53 and pRb, respectively, for degradation [15]. In HPV-positive 
tumours, an inverse correlation has been observed between positive infection with HPV 
and the mutation status of TP53 (Table 1) [20, 21]. As well, HPV-positive tumours were 
found to be dominated by activating mutations and focal amplifications of PIK3CA 
(56%), amplification of E2F1 (19%) and loss of TRAF3 (22%) [20]. 
Previous genetic characterizations of HNSCC have reported that the overall 
mutation rate of HPV-positive tumours was approximately half that of HPV-negative 
HNSCC malignancies (2.28 mutations/Mb and 4.83 mutations/Mb, respectively) [21], 
however, the most recent and arguably most comprehensive data regarding the genomic 
landscape of HNSCC concluded that the overall alteration rate did not differ significantly 
by HPV status in HNSCC tumour samples [20]. Taken together, the differences in the 
genetic profiles and etiologies between HPV-positive and HPV-negative HNSCC 
tumours, present the possibility of novel molecular targets and/or pathways being 
targeted for the treatment of HNSCC (Table 1). 
 
2.5 High Throughput Drug Testing in HNSCC 
 
 Cell lines are imperfect models of cancer; however, they have proven to be 
invaluable tools for cancer discovery. In 2012, two large studies performed by the Broad 
Institute (identified forthwith as the Cancer Cell Line Encyclopedia [CCLE]) and the 
Sanger Institute, involved screening a large number of cancer cell lines (947 and 639, 
respectively) against drug panels and correlating genetic and expression data with drug 
15 
 
response [23, 24]. These studies confirmed known drug correlations with molecular 
findings, in addition to uncovering novel associations.  
 Unfortunately, only a small number of drugs were tested in both the CCLE and 
Sanger studies (24 and 121, respectively) in a relatively small subset of available HNSCC 
cell lines (31 and 21, respectively) [23, 24]. Using the limited information pertaining to 
HNSCC, our laboratory interrogated data from Garnett et al. (2012), in an attempt to 
identify drugs with increased efficacy in HNSCC cell lines [23, 25]. Four drugs, Afatinib, 
Bosutinib, Docetaxel and Gefitinib, were found to have significantly higher activity in 
HNSCC cell lines versus all other cancer cell lines tested (Figure 6) [25]. 
 Docetaxel, an inhibitor of microtubule formation, is currently in routine clinical 
use for the treatment of HNSCC. In addition, Afatinib and Gefitinib, were also identified 
as preferentially active and both target epidermal growth factor receptor (EGFR), which 
is currently the only approved target for the treatment of head and neck cancers using 
Cetuximab [25]. The limited number of drug compounds tested in these large cancer cell 
line screens greatly limits the ability of novel, highly active agents being identified in 
HNSCC.  
 In addition, there were no HPV-positive HNSCC cell lines included in either of 
these studies. The importance of testing HPV-positive cell lines, in addition to HPV-
negative HNSCC lines, is absolutely critical given the fact that these cancers are 
molecularly distinct (Table 1). An expanded, HNSCC-specific study including both 
HPV-positive and HPV-negative HNSCC cell lines is needed, as well as an in vivo 
validation of the most promising candidates, in order to improve patient outcomes. 
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Figure 6. Compounds with increased activity in HNSCC cell lines. 
 
Using the data published by the Sanger group in 2012, Nichols and colleagues (2014) 
sought to identify drug compounds that demonstrated increased activity (lower IC50 
values) in HNSCC cell lines as compared to the remainder of the cancer cell line pool. 
The four drugs listed above were found to be preferentially active in HNSCC cell lines 
versus all other cancer cell lines screened (adapted from Nichols et al., 2014). 
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2.6 Current Treatment of HNSCC 
 
As mentioned previously, patients with HPV-positive tumours tend to be younger, 
healthier and possess a greater chance of surviving their disease (Figure 5) [5, 19]. As 
such, it is crucial that less harmful therapies are found for these patients, to help improve 
their overall quality of life. Additionally, HPV-negative patients are still at significant 
risk of cancer relapse and death (Figure 5) and also are at risk of severe treatment related 
toxicity thus highlighting the need for improved treatments for both HPV-positive and 
HPV-negative disease [2, 26, 27]. 
Contemporary treatments carry significant acute and late toxicities such as: 
mucositis, pain, vomiting, swallowing difficulty, hearing loss, bone necrosis, stroke, 
nerve injury and a risk of death of up to 3 % [27, 28]. It is evident that improved methods 
are needed for treating HNSCC patients including differential and ideally personalized 
treatment of HPV-positive versus HPV-negative tumours. Currently, only six drugs have 
been approved by the United States Food and Drug Administration (FDA) for the 
treatment of head and neck cancers including cytotoxic therapies such as cisplatin, 
methotrexate, 5-flurouracil, bleomycin, docetaxel as well as a single targeted agent, 
Cetuximab, which inhibits EGFR [26]. Our laboratory aims to develop a personalized 
approach to the treatment of HNSCC through high throughput drug testing and 
correlation of these results to the genomic alterations of the disease.  
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2.7 Targeted Cancer Therapy 
 
 Targeted therapies in cancer are agents that interfere with specific targets (often 
kinases) and/or pathways within cancer cells as opposed to non-selective traditional 
therapies, which simply target rapidly dividing cells and are often associated with severe 
toxicities. Targeted therapies are gaining traction in the development of anticancer drugs 
and form the basis of precision medicine. Precision medicine is an emerging approach to 
cancer therapy that involves the use of an individual tumour’s genetic profile to 
specifically tailor and optimize drug treatment through utilization of targeted agents 
found to target their specific genetic alterations [29]. An advantage of this type of 
treatment is that the alterations that are suspected to be directly responsible for the growth 
of a tumour are specifically targeted with an appropriate targeted therapy.  
 Many targeted therapies have been approved by the FDA for the treatment of 
various cancers such as imatinib, which targets the constitutively activated BCR-Abl 
protein in chronic myeloid leukemia (CML), trastuzumab, which blocks the function of 
the estrogen receptor in breast cancers with HER2 amplifications and vemurafenib, which 
targets the V600E activating mutation in BRAF for the treatment of melanoma and 
thyroid cancer (http://www.cancer.gov/about-cancer/treatment/types/targeted-therapies 
/targeted-therapies-fact-sheet#q4). Many additional compounds are currently under 
examination in clinical trials and even more are undergoing preclinical testing. 
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2.8 Precision Medicine in HNSCC 
 
 To date, EGFR is the only approved target for the treatment of head and neck 
cancers [25, 26]. Cetuximab, a monoclonal antibody therapy that inhibits EGFR, is 
routinely used in the clinic for the treatment of HNSCC patients [26]. In addition to 
EGFR, many novel targets and pathways are currently under investigation, in both 
clinical trials and preclinical testing, for the treatment of HNSCC including: vascular 
endothelial growth factor receptor (VEGFR), phosphatidylinositol-3-kinase (PI3K), Akt, 
mammalian target of Rapamycin (mTOR), MET, and insulin-like growth factor receptor 
(IGF-1R), for example [30]. The majority of molecules being investigated in these trials 
are ones targeting cellular targets with previous associations to cancer with some having 
been implicated as being important in HNSCC specifically, by recent publications of 
genomic analyses of HNSCC cell lines and patient tumours.  
 One such target, PI3K, has been of interest to many researchers since activating 
mutations and focal amplification of the PIK3CA gene, which encodes p110α, the 
catalytic subunit of PI3K, are prominent in HNSCC, especially in HPV-positive tumours 
(Table 1) [20]. Interestingly, when attempting to identify drugs with increased efficacy in 
HNSCC from the large-scale high throughput drug screening performed by Garnett and 
colleagues (2012), Nichols et al. (2014) found that AZD6482, a potent inhibitor of PI3-
kinase variant β, had significantly higher activity in PIK3CA mutant cancer cell lines as 
compared to PIK3CA wild-type cancer cell lines [23, 25]. This is an excellent example, 
teased out from a massive drug screening effort, of a targeted therapeutic agent having 
the potential to be useful against a specific genetic alteration, in this case, mutations and 
amplifications in the oncogene PIK3CA. 
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2.9 Project Rationale 
 
 The prospect of precision medicine in the treatment of HNSCC is looking 
increasingly more promising as progress is continuously being made in our understanding 
of HNSCC genomics as well as in molecular pharmacology, thus leading to a rapid 
expansion of new therapeutics being investigated [31]. Large-scale high throughput drug 
screens, specific to HNSCC, are necessary in order to identify new agents that exhibit 
increased activity in HNSCC cells and to identify novel cellular targets and/or pathways 
that can be interrogated in HNSCC. 
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3 HYPOTHESES AND OBJECTIVES 
 
3.1 Hypotheses 
 High throughput drug screening of HPV-positive and HPV-negative 
HNSCC cell lines will identify drugs that effectively control cell line 
proliferation. 
 HPV-positive and HPV-negative HNSCC are molecularly distinct and will 
differentially respond to a subset of therapeutic agents identified in a high 
throughput drug screen. 
 
3.2 Objectives 
 To identify drug compounds that are highly active in HNSCC cell lines 
using a high throughput drug screening platform. 
 To confirm potency of top drug hits through generation of dose response 
curves and determination of IC50 values. 
 To test a small subset of well characterized HNSCC cell lines against an 
expanded panel of drug compounds. 
 To investigate the mechanism of drug action of two drug hits in vitro 
using HNSCC cell lines. 
 To verify the effectiveness of Syk inhibitor, ER27319 maleate, at 
controlling HNSCC cell line proliferation in vivo using a cell line 
xenograft model. 
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4 MATERIALS AND METHODS 
 
4.1 HNSCC Cell Lines 
  
 Twenty-eight HNSCC cell lines were used in this study, the details of which can 
be found in Table 2 along with their original source, all available clinical information as 
well as their appropriate growth media. Each individual cell line was screened on the 
high throughput platform in Toronto, Ontario at the same passage number for all drug 
screens including the generation of dose response curves (see Sections 3.5 and 3.7). 
 
4.2 Compound Libraries 
 
 A custom-made compound library from Tocris Bioscience comprised of 1,185 
compounds and a proprietary kinase inhibitor library of 320 compounds (1,505 
compounds total) was used for high throughput drug screening. Two additional libraries, 
National Institutes of Health Clinical Collection and Prestwick compounds libraries were 
also used as an expanded drug panel (1,825 compounds total) to screen a subset of 6 well 
characterized HNSCC cell lines. All four compound libraries included compounds such 
as anticancer agents and kinase inhibitors that have all been previously tested in humans 
which helps to eliminate some regulatory hurdles for drug repurposing in HNSCC. The 
libraries were prepared as 1 mM stock solutions in 100% dimethyl sulfoxide (DMSO) 
and stored at –20°C in 384-well polypropylene plates (Sigma-Aldrich). 
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Table 2. HNSCC cell lines used in this study. 
 
Cell Line 
HPV 
Status 
Tumour Site 
(if available) 
Patient 
Information  
(if available) 
Growth Medium Source 
93-VU-147T Positive Floor of mouth Male, T4N2 DMEM/F12 VUMC 
HMS001 Positive Oropharynx (tonsil) Male DMEM/F12 Harvard Medical School 
UM-SCC47 Positive Lateral tongue Male, T3N1M0 DMEM/F12 University of Michigan 
UPCI:SCC090 Positive Oropharynx (tongue base) Male, T2N0 DMEM/F12 University of Pittsburgh 
UPCI:SCC154 Positive Oral cavity Male, T4N2 DMEM/F12 University of Pittsburgh 
Cal27 Negative Tongue Male, 56 DMEM/F12 ATCC 
Detroit 562 Negative Pharynx Female DMEM/F12 ATCC 
FaDu Negative Hypopharynx Male, 56 DMEM/F12 ATCC 
SCC-4 Negative Tongue Male, 55 DMEM/F12 ATCC 
SCC-9 Negative Tongue Male, 25 DMEM/F12 ATCC 
SCC-15 Negative Tongue Male, 55 DMEM/F12 ATCC 
SCC-25 Negative Hypopharynx Male, 56 DMEM/F12 ATCC 
SCC-61 Negative ------ ------ DMEM/F12 Yale 
Cal33 Negative Tongue Male, 69 DMEM+2mM L-glu DSMZ 
JHU006 Negative ------ ------ DMEM/F12 Johns Hopkins 
JHU011 Negative Larynx Male, T3N0 DMEM/F12 Johns Hopkins 
JHU029 Negative Oropharynx Male, T4N0 DMEM/F12 Johns Hopkins 
PCI6A Negative ------ ------ DMEM/F12 University of Pittsburgh 
PCI6B Negative Oropharynx Male, T3N3M0 DMEM/F12 University of Pittsburgh 
PCI13 Negative Oral cavity Male, T4N1M0 DMEM/F12 University of Pittsburgh 
PCI30 Negative ------ ------ DMEM/F12 University of Pittsburgh 
RF15A Negative ------ ------ DMEM/F12 University of Pittsburgh 
RF22A Negative ------ ------ DMEM/F12 University of Pittsburgh 
RF22B Negative Oral cavity Male, T4N1M0 DMEM/F12 University of Pittsburgh 
RF37A Negative ------ ------ DMEM/F12 University of Pittsburgh 
RF37B Negative ------ ------ DMEM/F12 University of Pittsburgh 
BICR56 Negative Tongue Female DMEM+2mM L-glu Public Health England 
PE/CA-PJ49 Negative Tongue Male, 57 IMDM+2mM L-glu Public Health England 
 
DMEM, Dulbecco’s Modified Eagle Medium; VUMC, VU University Medical Center Amsterdam; ATCC, 
American Type Culture Collection; DSMZ, Deutsche Sammlung von Mikroorganismen und Zellkulturen; 
IMDM, Iscove’s Modified Dulbecco’s Medium 
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4.3 Short-tandem Repeat Analysis 
 
Cell line identity was confirmed through short-tandem repeat (STR) profiling at 
The Centre of Applied Genomics in Toronto, Ontario, Canada, to ensure that there had 
been no contamination of the cell lines. All cell lines with published STR profiles were 
confirmed to be correct (Appendix 1). 
 
4.4 HPV Infection Status 
 
 Confirmation of HPV (type 16) infection status in HPV-positive HNSCC cell 
lines was confirmed by quantitative reverse transcription PCR (RT-PCR) using primers 
designed to target HPV type 16 and GAPDH transcripts (Table 3). HMS-001, UM-
SCC47, 93-VU-147T, UPCI:SCC090 and UPCI:SCC154 were all confirmed to be 
positive for HPV type 16, which is consistent with the literature. 
 
 
Table 3. RT-PCR primers used in this study. 
 
Target Oligonucleotide Sequence Notes 
HPV-16 TTGCAGATCATCAAGAACACGTA HPV forward primer 
HPV-16 GTAGAGATCAGTTGTCTCTGG HPV reverse primer 
HPV-16 AATCATGCATGGAGATACACCTACATTGCATGA HPV probe (JOE) 
TP53 CTCAGCATCTTATCCGAGTGGAAG TP53 forward primer 
TP53 TGGTACAGTCAGAGCCAACCTCA TP53 reverse primer 
TP53 CCCTATGAGCCGCCTGA TP53 probe (FAM) 
GAPDH GCTCATTTGCAGGGGGGAGCC GAPDH forward primer 
GAPDH CTGATGATCTTGAGGCTGTTG GAPDH reverse primer 
GAPDH TCTGCCCCCTCTGGTCATGCCCCCATGTTCGTCATGGGA GADPH probe (Cy5) 
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4.5 High Throughput Drug Screening 
 
All high throughput screening in this study took place at the S.M.A.R.T Facility 
in the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto, Ontario, 
Canada. 
 Cells were seeded five days prior to screening. Cells were then transported to 
Mount Sinai Hospital. Each HNSCC cell line was passaged twice prior to screening in 
their appropriate growth medium (Table 2) (Wisent Bioproducts, St-Bruno, Quebec) 
supplemented with 10% fetal bovine serum (FBS) (Wisent Bioproducts), 1% 
hydrocortisone (Multicell) and 100mg/mL penicillin and 100U of streptomycin (Wisent 
Bioproducts). Cells were then transported in a T175 flask (Sarstedt, Nümbrecht, 
Germany) filled completely with appropriate media since the entire cell line panel is 
adherent. Upon arrival in Toronto, all but approximately 30 mL of media was transferred 
into a sterile flask and used as cell resuspension media for cell seeding.  
 The following day, cells were washed with phosphate-buffered saline (PBS) 
(Wisent Bioproducts) and trypsinized (Wisent Bioproducts), resuspended to a 
concentration of 12,000 cells/mL and 50μL (600 cells/well) were seeded (Beckman 
BioMek FX, Mississauga, Ontario) into black 384-well clear-bottom plates (Corning®, 
Flintshire, United Kingdom). Each 384-well plate also had cells only and media only 
control wells on the two outer columns of the plate, respectively. Once seeded, cells were 
incubated at 37°C and 5% carbon dioxide for 24 hours. Following incubation, cells were 
treated with drug (1 compound/well) using an automated drug pinning device (Beckman 
Multimek, Mississauga, Ontario). For screening of the compound libraries, all 3,330 
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compounds screened were tested at a single, final concentration of 4 μM. For the 23 
compounds selected for hit confirmation, 10 different drug concentrations were tested 
ranging from 15 nM to 8 μM. Cells were incubated with the drug compounds for 48 
hours at 37°C and 5% carbon dioxide (Figure 7). 
 
4.6 AlamarBlue Viability Assay 
 
 AlamarBlue (Life Technologies, Burlington, Ontario) is a metabolic agent that is 
reduced by increased mitochondrial activity in viable cells [32]. AlamarBlue uses the 
natural reducing power of live cells to convert its inactive ingredient resazurin (blue, 
indicating non-viable cells) to its active form, resorufin (red, indicating viable cells), 
which generates a quantitative measure of cytotoxicity and viability [32]. Following 
addition of drug on day 1 of high throughput drug screening and the 48 hour incubation 
period, alamarBlue was added to each well (5%) (Beckman BioMek FX) and allowed to 
incubate for 4 hours (Figure 7). Fluorescence signals were then measured using a 
Pherastar microplate reader (BMG Labtech, Ortenburg, Germany) with peak excitation at 
570 nm and peak emission at 585 nm. For determination of drug activity, the average of 
all media only control wells was subtracted from all test wells and the percent of drug 
activity, whether positive or negative, was then determined by calculating the change in 
fluorescence values between treated cells and untreated cells. 
 The top 5% (78/1,505) of compounds found to display the greatest average 
percent reduction in cellular growth across the entire HNSCC cell line panel were 
deemed hit compounds (Appendix 2). 
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Figure 7. Protocol for high throughput drug screening of HNSCC cell lines. 
 
Cell lines were seeded from frozen stocks and passaged twice prior to screening. Cells 
were seeded at 12,000 cells/mL in 384-well plates and allowed to incubate for 24h at 
37°C and 5% CO2. On day 1, drug compounds were added to each well at a final 
concentration of either 4 μM or 10-point concentrations ranging from 15nM to 8 μM and 
incubated under the same conditions. After 48h, cells were treated with alamarBlue, 
incubated for 4h at 37°C and 5% CO2 and fluorescence measurements taken. Untreated 
cell wells were used as a baseline for cellular proliferation. 
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4.7 Dose Response Curves 
 
 Following the drug screening methodology described above, 23 of the 78 hit 
compounds (Appendix 2) were selected for drug validation based on three criteria: 
universal potency (compounds that were broadly effective across majority of cell lines), 
differential activity (compounds that were extremely potent in some cell lines while 
completely ineffective in others) and compounds affecting the PI3K/Akt/mTOR pathway. 
 HNSCC cell lines underwent the identical drug screening methodology as 
described above (Figure 7), however, on day 1, drugs were added at 10 doses in the range 
of 15 nM to 8 μM for the 23 drug compounds selected for validation. Cells were then 
incubated under the same conditions for 48h at which point florescence readings for cell 
viability were measured and data collected. Cell viability in my assays was measured 
with alamarBlue (Life Technologies). Absorbance measurements were taken and dose 
response curves were calculated for these top hits to confirm compound activity in vitro 
in HNSCC cell lines. The IC50 (half maximal inhibitory concentration) for each agent was 
then determined by sigmoidal regression using GraphPad Prism v6.0. In cases where an 
IC50 value could not be definitively extrapolated, the normalized raw data was examined 
to determine a drug sensitivity dose range. In rare cases, drug sensitivity data could not 
be converged using non-linear regression so no conclusions on drug sensitivity in these 
cases could be drawn. 
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4.8 Western Blot Analysis 
 
 Cal27 cells were seeded prior to the experiment in T25 flasks (Sarstedt). Cells 
were then treated with ER27319 maleate (0.62 μM) for 0.08, 0.16, 0.33, 1, 3, 6, 12, 24, or 
48 hours. An additional flask was maintained as an untreated control. Cells were lysed at 
each time point in lysis buffer containing radioimmunoprecipitation assay (RIPA) buffer 
and protease inhibitor (1:250). Total protein content was quantified using a protein assay 
reagent (BioRad) in a Bradford assay. Equal amounts of protein (40 μg) were resolved on 
a 4-12% gradient SDS-polyacrylamide gel (Life Technologies). The separated proteins 
were then transferred to a nitrocellulose membrane (GE Healthcare, Toronto, Ontario) 
and blocked for 1 hour at room temperature with either 5% w/v milk (Bioshop, 
Burlington, Ontario) or 5% w/v bovine serum albumin (Sigma-Aldrich, Oakville, 
Ontario), for total and phosphorylated protein, respectively. The membrane was then 
incubated with primary antibody (Table 4) (1:1000) overnight at 4°C followed by 
incubation with the secondary, goat anti-rabbit- 
 
 
 
Table 4. Antibodies used in this study. 
 
Antibody Label 
Molecular 
Weight (kDa) 
Host Species 
(Isoform) 
Commercial Source 
Dilution 
Used 
Syk (D3Z1E) 72 Rabbit Cell Signaling 1:1000 
Phospho-Syk (Tyr323) 72 Rabbit (IgG) Cell Signaling 1:1000 
Phospho-Syk (Tyr525/526) 72 Rabbit Cell Signaling 1:1000 
Anti-Rabbit IgG --- Goat Cell Signaling 1:5000 
α-tubulin 50 Mouse Sigma-Aldrich 1:2000 
Anti-goat -- Donkey Jackson Laboratories 1:5000 
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horseradish peroxidase (HRP) (Cell Signaling, Danvers, Massachusetts) (1:5000) for 1 
hour at room temperature. Finally, membranes were developed using a 
chemiluminescence reagent (Millipore Luminata® Crescendo, Etobicoke, Ontario). To 
ensure equal loading for each lane, membranes were stripped, re-blocked, probed with α–
tubulin (1:2000) and incubated with goat anti-mouse-HRP (1:5000) for 1 hour at room 
temperature and then developed in the same manner described previously. 
 
4.9 Quantitative Reverse Transcription PCR 
 
 Endogenous transcript levels of TP53 were measured, using quantitative RT-PCR, 
to verify that cellular transcript levels were increasing upon treatment with NSC146109 
hydrochloride. Cal27 cells were seeded prior to the experiment in T25 flasks (Sarstedt). 
The following day, cells were treated with NSC146109 hydrochloride (0.98 μM) for 0.5, 
1, 3, 6, 12, 24, or 48 hours. An additional flask was maintained as an untreated control. 
Cells were lysed at each time point using QuickExtract RNA extraction kit (Epicentre, 
Madison, Wisconsin) to obtain RNA. This RNA was for construction of complementary 
DNA (cDNA) by reverse transcriptase PCR. This cDNA was then used as template in a 
multiplex quantitative PCR reaction (QuantiTect Multiplex PCR Kit, Qiagen, Toronto, 
Ontario) using primer and probes designed to target TP53 (Solaris, GE Dharmacon, 
Ottawa, Ontario) and GAPDH transcripts (Table 2). 
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4.10   Cell Line Xenografts 
 
 Cal33 were seeded from frozen stocks in Dulbecco’s Modified Eagle Medium 
(DMEM) (Multicell) supplemented with heat inactivated FBS (Multicell), 1% 
hydrocortisone (Multicell) and 100mg/mL penicillin and 100U of streptomycin 
(Multicell). After initial cell seeding, cells were maintained in complete media without 
antibiotics. Cells were collected, spun down and resuspended in PBS (Multicell). Eight 
week old BALB/c athymic mice (Charles River, Sherbrooke, Quebec) were obtained and 
1 x 10
6
 cells in 100 uL in PBS were injected into each flank (2 injections per mouse). 
Mice were monitored until tumours were palpable (8 days) at which time tumours were 
measured for a tumour baseline evaluation and drug treatment was initiated. There were 
10 mice for each of the 3 treatment groups: vehicle control dose, 10 mg/kg dose, and 40 
mg/kg (Table 5). 
 ER27319 maleate was administered at 10 mg/mL and 40 mg/mL doses by oral 
gavage along with the control group receiving PBS by oral gavage (Table 5). Mice were 
dosed daily (5 days/week) and tumours measured twice a week with digital calipers 
(Mitutoyo, Japan). ER27319 maleate treatment continued until day 26, at which time 
mice were sacrificed by CO2 asphyxiation. Visible tumours, along with the liver, spleen, 
heart and lungs were collected and formalin fixed for preservation of tissue for potential 
investigations in the future. 
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Table 5. Dosing regimens for in vivo cell line xenografts. 
 
Treatment Group Dose (mg/kg) 
# of Mice 
per group 
Treatment 
Schedule 
Termination 
 
Placebo (PBS) --- 
 
10 
 
Daily oral 
gavage 
(5 days/week) 
All mice were sacrificed 
at day 26 of ER27319 
maleate treatment 
 
ER27319 maleate 10 
 
ER27319 maleate 40 
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5 RESULTS 
 
5.1 Large-scale, high throughput drug screening identified 
highly active agents in HNSCC cell lines 
 
 Of the 1,505 compounds screened, 78 drugs were observed to reduce cellular 
growth by greater than 20% in at least 25% of HNSCC cell lines screened (top 5% of 
active compounds screened) (Appendix 2).  These compounds were deemed ‘hit’ 
compounds and found to be active in HNSCC cell lines.  
 The list of compounds was then narrowed down 23 hit compounds to move 
forward for drug validation studies (Table 6), based on three criteria: universal potency 
(compounds that were extremely potent across majority of the cell line panel), differential 
activity (compounds that were highly active in some cell lines while completely 
ineffective in others) or compounds affecting the PI3K/Akt/mTOR signaling pathway (a 
frequently altered pathway in HNSCC cells) (Table 1). These 23 hit compounds were 
selected for validation based upon the above criteria as well as their potential as 
therapeutic agents in other malignancies as described in the literature.  
 Dose response curves were generated (Figure 8) for each of the 23 compounds in 
28 HNSCC cell lines and IC50 values were determined (Figure 9). Validation of these 23 
drug hits proved successful as the majority of compounds remained highly active (IC50 < 
2 μM) in the validation step of my high throughput drug screening (Figure 9). 
Additionally, the trends of universal potency as well as differential activity, two of the 
criteria used for selection of these compounds for validation, were found to continue 
upon determination of drug sensitivity in these cell lines (Figure 9). 
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Table 6. Drug hits selected for drug validation studies. 
 
Selection 
Criteria 
Drug Target 
Pathway/Target 
Affected 
Clinical Trial 
status  
(# in HNSCC)
1
 
U
n
iv
er
sa
l 
P
o
te
n
cy
 
Pyrrolidinedithiocarbamate ammonium NF-kB NF-kB 0 
NSC146109 hydrochloride p53 p53 levels 0 
Ro 31-8220 mesylate PKC Signalling 6 
Ouabain Na,K-ATPase Ion channels 3 
BNTX maleate 
δ1 opioid 
receptor 
Opiod receptor 0 
SCS GABAA NTM Receptor 0 
ER27319 maleate Syk Immune signalling 0 
JTC 801 NOP receptor Opiod receptor 0 
Ryuvidine CDK4 Cell cycle 0 
BI 78D3 c-JNK MAPK Signalling 0 
D
if
fe
re
n
ti
al
 A
ct
iv
it
y
 
NSC 95397 Cdc25 Cell cycle 0 
SCH 79797 dihydrochloride PAR1 Platelets; T cells 0 
MK-1775 Wee1 Cell cycle 21(2) 
TCS2312 dihydrochloride Chk1,2 Cell cycle 3 
Bosutinib Bcr-Abl, Src Signalling 35 
AZD4547 FGFR Signalling 10 
Foretinib 
MET, 
VEGFR2 
MAPK Signalling 11(1) 
RDEA119 MEK MAPK Signalling 3 
P
I3
K
-p
at
h
w
ay
 
sp
ec
if
ic
 
NVP-BEZ235 PI3k/mTOR PI3K/AKT/mTOR 22 
GDC-0941 bismesylate PI3K PI3K/AKT/mTOR 17 
Rapamycin mTOR PI3K/AKT/mTOR 1759(41) 
A-443654 AKT PI3K/AKT/mTOR 0 
BYL719 PI3K PI3K/AKT/mTOR 30(6) 
 
1Refers to the total number of publicly and privately supported clinical studies of human participants that 
are currently ongoing as of June 20, 2015 with the number in parentheses referring to the number of trials 
intervening with head and neck cancers (www.clinicaltrials.gov). 
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Figure 8. Representative dose response curves from drug screening for hit 
confirmation. 
 
A. Examples of dose response curves with a sigmoidal decrease in percent activity of cell 
growth where IC50 values could be confidently extrapolated from the modeled data.  
B. Examples of dose response curves that were found to be ambiguous meaning that 
specific IC50 values could not be calculated from this modeled data. In these situations, 
normalized raw data was reviewed and a drug sensitivity concentration range was 
determined to resolve the sensitivity of a particular cell line. In some cases the raw data 
simply could not be resolved and the result was ‘not converged’ where Prism could not 
converge a line of best fit to the data. 
  
IC50 = 1.49 IC50 = 1.54 IC50 = 3.31 
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Figure 9. Sensitivity of HNSCC cell lines to 23 compounds identified by high 
throughput drug screening.  
 
Ten-point dose response curves were generated for 23 drug compounds identified as 
being highly active in the HNSCC cell line panel where cellular viability was measured 
using alamarBlue. Criteria for how drugs were selected can be seen along the left. IC50 
values, in micromolar, for each agent were determined by non-linear regression. HPV-
positive HNSCC cell lines are denoted as pink and compounds selected for preclinical 
development in blue. Green represent exquisite sensitivity (IC50 < 2 μM), yellow are 
moderately sensitive (IC50 = 2-7.99 μM) and grey are resistant (IC50 > 8 μM, which was 
the highest concentration tested). Hatched squares represent data that was not converged, 
which occurs when non-linear regression cannot converge on a line of best fit. 
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5.2 HNSCC cell lines are sensitive to known 
chemotherapeutics 
 
 A subset of 10 compounds identified in the list of 78 hit compounds were found 
to be well-established chemotherapeutic agents that are currently, or have been routinely 
used in the treatment of various cancers, including head and neck cancers (Table 7; 
Appendix 2). Drugs such as daunorubicin, vincristine sulfate, etoposide, and irinotecan 
are used for the treatment of different malignancies and were found to be highly active in 
HNSCC cell lines (http://www.cancer.gov/about-cancer/treatment/drugs). In addition, 
doxorubicin and paclitaxel were identified as drug hits and were/are clinically used for 
the treatment of head and neck cancers specifically. These compounds were found to be 
extremely efficient at controlling HNSCC cell line proliferation in vitro, many of which 
displayed high activity across the majority of the cell line panel. 
 Although 10 known chemotherapeutic drug compounds were found to be active in 
the current screen, it was observed that some of these clinically-used compounds were 
not as effective as many other hit compounds (Appendix 2). For example, the drug 
Taxol® (paclitaxel, NSC125973) was found to be one of the 78 hit compounds; however, 
a multitude of other compounds that were screened displayed much higher activity across 
the panel of HNSCC cell lines (Appendix 2). Additionally, both cisplatin and carboplatin, 
which are the most frequently used chemotherapeutics in HNSCC, were included in my 
drug screening at 4 μM but were not identified as hits using my selection criteria. 
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Table 7. Hit drug compounds currently used for the treatment of cancer.  
 
Drug Name 
Cellular Pathway 
and/or Target 
Number of Clinical 
Trials (head and neck 
specific) 
Treatment Uses in Cancer 
Alternate  
Drug Name(s) 
Actinomycin D RNA polymerase 46 
Ewing’s sarcoma, testicular, 
melanoma, soft tissue sarcoma 
etc 
------ 
Camptothecan DNA topoisomerase I 1223 (68) Colon, rectal Irinotecan 
Clofarabine DNA/RNA synthesis 149 ALL1 ------ 
Daunorubicin DNA/RNA synthesis 248 ALL, AML2 ------ 
Doxorubicin DNA topoisomerase II 1576 (15) 
Bladder, breast, head and neck, 
liver, lungs, ovary, thyroid etc 
------ 
Etoposide DNA topoisomerase II 1135 (5) 
Testicular, bladder, prostate, 
lung, stomach, uterine 
------ 
Homoharringtonine Protein synthesis 18 CML3 
Omacetaxine 
mepesuccinate 
Taxol Microtubules 2482 (210) 
Breast, ovarian, lung, bladder, 
prostate, head and neck, 
melanoma etc 
Paclitaxel,  
NSC 125973 
Vinblastine sulfate Microtubules 230 (2) 
Hodgkin’s disease, non-
Hodgkin’s lymphoma, 
testicular, breast, lung, head 
and neck, bladder etc 
------ 
Vincristine sulfate Microtubules 861 (1) 
Acute leukemia, multiple 
myeloma, thyroid etc 
------ 
 
1ALL, acute lymphoblastic leukemia; 2AML, acute myelogenous leukemia; 3CML, chronic myelogenous 
leukemia. 
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5.3 HNSCC cell lines are sensitive to drugs targeting well-
known pathways and targets in cancer 
 
 The majority of drug hits identified in the high throughput screen could be 
grouped together based upon the pathway(s) and/or target(s) they are known to affect 
within the cell (Figure 10). Many of the targets and pathways found to be affected by the 
top hits were ones that have been previously implicated in cancer and HNSCC in 
particular. Some of the most prominent targets within the top drug hits were compounds 
interfering with the function of various receptor tyrosine kinases (RTK) including EGFR 
and VEGFR. Additionally, compounds affecting cell cycle regulation, cytoskeleton 
assembly, NF-κβ signaling, and DNA topoisomerase function were all found to be highly 
active in HNSCC cell lines (Figure 10). As well, drug compounds found to inhibit protein 
kinase C (PKC) and interfere with protein synthesis were found to be highly active. 
 
5.4 High throughput screening identified highly active 
agents targeting novel cellular targets in HNSCC 
 
 In addition to identifying targets and pathways previously associated with cancer, 
and HNSCC specifically, several novel targets were also identified in HNSCC cell lines 
(Appendix 2). Such novel HNSCC targets included: protease-activated receptor (PAR1), 
transient receptor potential cation channel subfamily V member 1 (TRPV1), somatostatin 
receptor 4 (sst4), nociceptin receptor, SETD8, GABAA receptor, interleukin 8 receptor 
beta (CXCR2), p38α, excitatory amino acid transporter (EAAT2/4), N-methyl-D- 
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Figure 10. Hit compounds categorized based upon their cellular target(s). 
 
HNSCC cell lines were screened, in duplicate, according to the methodology described in 
Figure 7. Compounds that were active in at least 25% of the HNSCC cell line panel, in 
both experimental replicates, were classified as ‘hits’. Seventy-eight hits were identified 
as drug hits (Appendix 2) and could be grouped based on the pathway(s) and/or target(s) 
they are known to affect within the cell, as shown above. 
  
41 
 
aspartate receptor (NMDA), fatty acid amide hydrolase (FAAH), retinoic acid receptor 
gamma (RARγ) as well as compounds that were anthelmintics, dopamine receptor 
antagonists and inhibitors of DNA methylation (Appendix 2, 3). All of these compounds 
were found to display activity in vitro throughout the HNSCC cell line panel. 
 
5.5 Select HNSCC cell lines were less sensitive to 
chemotherapeutics 
 
 Many of the HNSCC cell lines that were tested displayed patterns of extreme to 
moderate sensitivity to the top 30 of 78 compounds tested (Appendix 2). In contrast, 3 
HNSCC cell lines, SCC-4, SCC-25 and PCI6A, were found to be strikingly less sensitive 
to many of the top 78 compounds. These cell lines were observed to have similar raw 
fluorescence intensity values as all other HNSCC cell lines screened when left untreated 
thus inferring comparable cellular growth. Additionally, these cell lines displayed this 
insensitivity trend in both experimental replicates. SCC-25 continued to be relatively less 
sensitive than the remainder of the HNSCC cell line panel when treated with the top 23 
drug compounds selected for validation (Figure 9). 
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5.6 Expanded screening identified compounds with 
preferential activity in either HPV-positive or HPV-negative 
HNSCC cell lines 
 
 With the knowledge that HPV-positive and HPV-negative HNSCC tumours arise 
by distinct mechanisms and possess differing genetic landscapes (Table 1), as previously 
discussed, I expected to uncover compounds that were exclusively active in either HPV-
positive or HPV-negative HNSCC cell lines. However, from the preliminary screening 
and initial hit list, I was unable to identify any compounds that displayed any significant 
preferential activity in either HPV-positive or HPV-negative cell lines.  
 To help resolve this, I performed an expanded drug screen of 1,825 additional 
compounds against a subset of HNSCC cell lines, including both HPV-positive and HPV-
negative lines. Hits were classified as compounds that had a B score, which is a variation 
of a Z score that takes into account positional plate errors, that was 3 standard deviations 
below the experimental mean of cellular proliferation (Appendix 3). From the hit list that 
was generated, 5 compounds were found to be preferentially active in HPV-negative cell 
lines while only one compound, hycanthone, was found to be exclusively active in 2 of 
the 3 (93-VU-147T and HMS001) HPV-positive cell lines tested (Table 8, Appendix 3). 
Hycanthone exhibited negligible activity in all three HPV-negative HNSCC cell lines 
tested. There is some literature investigating this compound, however, it does not appear 
to have been explored in context of head and neck cancers thus providing a potential 
avenue for further research in HNSCC. 
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Table 8. Drug compounds with preferential activity in either HPV-positive (pink) or 
HPV-negative (white) HNSCC cell lines. 
 
Drug Name Function/Target 
HNSCC cell line 
specificity 
Puromycin dihydrochloride Antibiotic HPV-negative 
6-azauridine Anti-viral HPV-negative 
Primaquine diphosphate Anti-parasitic HPV-negative 
Rosiglitazone maleate Anti-diabetic HPV-negative 
Letrozole Aromatase inhibitor HPV-negative 
Hycanthone DNA/RNA synthesis HPV-positive 
 
 
5.7 NSC146109 hydrochloride effectively inhibited HNSCC 
cell line growth in vitro 
 
 NSC146109 hydrochloride was identified as highly active across the HNSCC cell 
line panel with an average reduction in cellular growth of approximately 84% (Appendix 
2). Based on its universal potency in the cell line panel, as well as its role in reactivating 
p53 [33], this compound was selected as one of the 23 compounds to move forward for 
drug validation studies (Table 6, Appendix 2). Dose response curves were generated and 
IC50 values calculated for all HNSCC cell lines against NSC146109 hydrochloride and 
not unexpectedly, every cell line in the panel was found to be sensitive; with the majority 
of cell lines having IC50 values below 2 μM (Figure 9).  
 Quantitative RT-PCR was performed in an attempt to quantify TP53 levels in 
both treated and untreated Cal27 cells. Control GAPDH transcripts could be efficiently 
detected using quantitative PCR, which indicates that the RNA extraction and cDNA 
production protocols were both successful, as seen in Figure 11. Unfortunately, TP53  
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Figure 11. Representative amplification plots of TP53 and GAPDH transcripts. 
 
Cal27 cells were treated with NSC146109 hydrochloride (0.98 μM), cells were lysed and 
RNA collected at multiple time points. Complementary DNA was then generated by RT-
PCR. This cDNA was then used as template in a multiplex quantitative PCR reaction 
using primer and probes designed to target TP53 (red) and GAPDH (black) transcripts. 
Endogenous transcript levels of TP53 were measured in an attempt to verify that cellular 
transcript levels increased upon treatment with NSC146109 hydrochloride. The above 
amplification plots are representative of all amplification curves for both GAPDH and 
TP53 where GAPDH could be successfully detected, thus indicating successful RNA 
extraction, cDNA production and qPCR. Unfortunately, TP53 transcripts were not 
efficiently detected in any sample tested. 
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transcript levels were too low to be detected at all time points in both treated and 
untreated samples, so no conclusions could be made regarding the effect of NSC146109 
hydrochloride treatment on TP53 transcript levels in Cal27 HNSCC cells in vitro (Figure 
11).  
 
5.8 ER27319 maleate potently suppressed HNSCC cell line 
proliferation in vitro 
 
 ER27319 maleate was identified as a highly potent compound following initial 
screening of my HNSCC cell line panel. On average, this compound was found to reduce 
cellular growth by approximately 77% of the HNSCC cell lines screened (Appendix 2). 
This compound was selected as one of the 23 compounds to move forward for drug 
validation studies (Table 6) based on the high activity observed at a single dose in 
preliminary screening (Appendix 2). Dose response curves were generated and IC50 
values calculated for ER27319 maleate against all HNSCC cell lines. Almost every 
HNSCC cell line tested was found to be sensitive with the majority of lines having IC50 
values below 3 μM (Figure 9).  
 Next, I sought to investigate the cellular mechanism of ER27319 maleate in 
HNSCC cell lines in vitro by examining spleen tyrosine kinase (Syk) phosphorylation in 
the presence and absence of ER27319 maleate with western blot analysis [34]. 
Endogenous Syk was detected at all time points in both the presence and absence of drug 
(Figure 12). Protein loading was observed to be sufficient and uniform based on tubulin  
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Figure 12. Effects of ER27319 maleate on phosphorylation of Syk. 
 
Cal27 cells were treated with ER27319 maleate at 0.62 μM for 0.08, 0.16, 1, 3, 6, 12, 24, 
or 48 hours. An additional flask was maintained as an untreated control. Cells were lysed 
and equal amounts of protein were loaded into each well. Phosphorylated Syk was probed 
for using two antibodies; however, phosphorylated Syk in untreated samples was not 
detectable so no conclusions could be confidently drawn. Levels of endogenous Syk were 
also examined and tubulin was used as a loading control. 
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detection; however, I was unable to adequately visualize many of the potential 
phosphorylated Syk proteins. Although it initially appeared as though addition of 
ER27319 maleate was inhibiting Syk phosphorylation at both early and late time points 
(0.08, 24, 48 hours at the Y525/526 phosphorylation sites); untreated phospho-Syk was 
not detected, so no conclusions regarding the effect of ER27319 maleate on Syk 
phosphorylation could be definitively drawn (Figure 12). 
 
 
5.9 ER27319 maleate suppressed tumour growth in vivo 
 
 Using Cal33 cell line xenografts, ER27319 maleate was orally administered at 10 
mg/kg and 40 mg/kg doses. Mice were dosed daily for 26 days with tumours measured 
twice weekly (Table 5). ER27319 maleate was found to be extremely well tolerated, at 
both doses, by all mice tested. For all tumour measurements taken (days 5-26), paired 
Student’s t-tests were performed comparing the average percent increase in tumour 
volume (mm
3
) for both doses of ER27319 maleate-treated tumours to untreated control 
tumours (Table 9). Mice treated with ER27319 maleate at 40 mg/kg were found to have 
significantly decreased percent increase in tumour growth as compared to control 
tumours for every tumour measurement taken (Figure 13).  
 Additionally, mice treated with low dose ER27319 maleate (10 mg/kg) were 
observed to have significantly decreased tumour growth as compared to untreated mice at 
days 5, 8, 19, and 22. This inhibition in tumour growth provides excellent support for my 
in vitro drug screening and serves as a starting point where I plan to test higher doses of 
ER27319 maleate to see if tumour growth can be further decreased or even halted 
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completely. Preliminary investigation into ER27319 maleate at a dose of 70 mg/kg (n=5) 
found that the dose was tolerated well over 6 days of treatment. 
 
 
 
Table 9. Mean tumour volumes and standard errors as percent increase from 
untreated baseline tumour measurements. 
 
Day of  
ER27319 maleate 
Measurement 
Control  
(% increase) 
10 mg/kg 
(% increase) 
40 mg/kg 
(% increase) 
5 40.8 ± 12.6 -3.6 ± 7.3* -21.2 ± 8.6*** 
8 67.2 ± 14.0 20.3 ± 10.0** -0.7 ± 13.7** 
12 121.7 ± 25.1 63.1 ± 15.6 10.7 ± 15.2** 
15 180.0 ± 31.3 109.1 ± 16.4 30.6 ± 17.1*** 
19 225.6 ± 36.8 128.2 ± 21.0* 59.2 ± 21.0*** 
22 296.0 ± 44.9 164.8 ± 29.7* 76.9 ± 28.0*** 
26 341.0 ± 52.5 237.9 ± 38.1 125.0 ± 39.0** 
 
* for p<0.05; ** for p<0.01; *** for p<0.001 as compared to untreated tumour growth  
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Figure 13. ER27319 maleate effectively controls tumour growth in vivo. 
 
Eight-week old athymic mice were injected with Cal33 cells (1 x 10
6
) on each flank (2 
tumours/mouse). Once tumours were palpable, ER27319 maleate was administered orally 
at 10 mg/kg and 40 mg/kg doses daily. Tumours were measured twice weekly and 
tumour growth was normalized for each individual tumour to its original untreated 
tumour measurement for determination of the percent increase for each individual 
tumour. The average percent increase of tumour volume for all 20 tumours per treatment 
group was calculated and plotted along with the standard error. Asterisks indicate a 
statistically significant difference from untreated control tumour growth (p < 0.05). 
 
 
  
n = 20 
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6 DISCUSSION 
 
 HNSCC affects approximately 600,000 new individuals each year, and includes 
malignancies arising in the oral cavity, nasal cavity, lip, paranasal sinuses, salivary 
glands, pharynx, and larynx [2]. Currently, treatment is limited to chemotherapy, 
radiation therapy and/or surgery. High throughput drug screening has the potential to 
identify highly active agents for the treatment of HNSCC, a malignancy that has not seen 
improvement in its survival rates in decades, and is in desperate need of novel therapeutic 
options.  
 In an effort to identify novel targets and pathways implicated in HNSCC, I 
performed high throughput drug screening on a panel of HNSCC cell lines against 1,505 
FDA-approved drug compounds. In addition, I screened a subset of HNSCC cell lines on 
an expanded drug panel including an additional 1,825 compounds in an effort to identify 
compounds with preferential activity in either HPV-positive or HPV-negative HNSCC 
cell lines. Following my preliminary screen and identification of hit compounds, I then 
selected 23 compounds to be confirmed as hits through generation of dose response 
curves. Finally, two compounds, ER27319 maleate and NSC146109 hydrochloride were 
selected as lead drug compounds to move forward into preclinical development. 
 
6.1 Summary of Experimental Findings 
 
 Large-scale, high throughput drug screening identified highly active agents in 
HNSCC cell lines. 
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 HNSCC cell lines are sensitive to known chemotherapeutic agents. 
 HNSCC cell lines are sensitive to drugs targeting known pathways and targets in 
cancer. 
 High throughput screening identified highly active agents targeting novel cellular 
targets in HNSCC. 
 Select HNSCC cell lines were less sensitive to chemotherapeutics. 
 Expanded screening identified compounds with preferential activity in either 
HPV-positive or HPV-negative HNSCC cell lines 
 NSC146109 hydrochloride effectively inhibited HNSCC cell line growth in vitro. 
 Syk inhibitor, ER27319 maleate, potently suppressed HNSCC cell line 
proliferation in vitro and in vivo. 
 
6.2 Implications of Experimental Findings 
 
6.2.1 High throughput drug screening identified highly active 
agents in HNSCC cell lines including known therapeutics 
and compounds targeting well-known pathways in cancer 
 
Preliminary drug screening at a single concentration resulted in the identification 
of 78 hit compounds that demonstrated activity against HNSCC cell lines in vitro. Many 
of these highly active compounds affected cellular pathways and targets previously 
implicated in cancer and even HNSCC specifically. Chemotherapeutic drugs such as 
daunorubicin, doxorubicin, Actinomycin D, Etoposide and Taxol were found to be active 
against HNSCC cell lines in vitro and have all been extensively explored and approved 
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for the treatment of a variety of malignancies (Table 7). Having such chemotherapeutic 
agents appear within the top drug hits helps to provide internal positive controls for my 
high throughput screening experiments since drug compounds known and confirmed to 
be effective at inhibiting cancer cell growth, are proving to be highly potent on this high 
throughput platform.  
Interestingly, although screening identified known chemotherapeutics among the 
hit compounds, some of these clinically established drugs were found to be relatively less 
potent that many other hit compounds (Appendix 2). For example, Taxol® (Paclitaxel, 
NSC125973) is a compound commonly used for the treatment of breast, ovarian, and 
non-small cell lung cancers as well as head and neck cancers 
(http://www.cancer.gov/about-cancer/treatment/drugs/paclitaxel). This compound has 
been in clinical use for over 30 years and there are currently 2,482 clinical trials ongoing, 
with 210 trials for its use in the treatment of head and neck cancers 
(https://clinicaltrials.gov/ct2/results?term= Paclitaxel&Search=Search). Despite Taxol® 
being identified as a hit compound; there were many additional compounds that appeared 
as hits in the screen that had higher activity across the HNSCC cell line panel. In 
addition, cisplatin and carboplatin, which are standard of care chemotherapeutics for 
HNSCC, were included in my high throughput drug screening. However, neither drug 
was found to be a hit when screened at a single dose of 4 μM. Since these drug 
compounds are routinely used as the workhorses for the treatment of head and neck 
cancers, the most likely explanation is that these drugs were not at optimal concentrations 
to effectively control HNSCC cell line proliferation. 
53 
 
Although this study was limited to in vitro experiments at a single drug 
concentration for the characterization of drug potency of these established 
chemotherapeutics in HNSCC cell lines, these results suggest that there are potentially a 
multitude of currently uncharacterized compounds in HNSCC that may be significantly 
more effective than current chemotherapeutics at controlling HNSCC growth and warrant 
further investigation by our laboratory. 
 Next, I wanted to confirm the activity of a subset of drug compounds through 
generation of dose response curves to characterize the sensitivity of each HNSCC cell 
lines to the top 23 drug compounds selected for hit confirmation. Compounds selected for 
hit confirmation were selected based on three criteria: universal potency, differential 
activity and PI3K-pathway specific, and IC50 values were calculated.  IC50 values provide 
a valuable quantitative measure of the effectiveness of a drug compound at inhibiting a 
specific biological or biochemical function. Overall, the methodology of high throughput 
drug screening for drug hit identification and validation of top drug hits used in this study 
proved successful as majority of the top compounds were confirmed as being moderately 
(IC50 = 2 – 7.99 μM) to exquisitely sensitive (IC50 < 2 μM) across the entire HNSCC cell 
line panel (Figure 9). Confirmation of drug activity is essential for determination of the 
concentration of drug required for efficient control of HNSCC cell line proliferation in 
vitro as well as to provide sufficient preclinical data prior to testing drug activity in vivo 
using mouse xenografts. 
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6.2.2 High throughput screening identified highly active agents 
targeting novel cellular targets in HNSCC 
 
 In addition to identifying known chemotherapeutics, my large-scale screening 
identified many highly active compounds targeting novel cellular targets within the cell. 
The automated nature of the high throughput screen enabled me to screen over 3,300 
compounds in total, which facilitated the identification of many novel targets that may 
play a significant role in HNSCC including PAR1, CXCR2, p38α, EAAT2/4 and RARγ, 
and others (Appendix 2, 3). Some of these targets have been previously explored in the 
context of other diseases or even other malignancies, however, little to no evidence of 
their role in HNSCC could be found in the literature. Further investigation into these 
compounds and novel cellular targets is required to evaluate their efficacy and confirm 
their activity in HNSCC. 
 
6.2.2.1 Anthelmintics 
 
 Anthelmintics are a class of drugs that function by removing internal parasites 
and/or parasitic worms from the body without causing any significant damage to the host 
organism [35]. Many populations in developing nations suffer from such helminth 
infections as well as their co-morbidities such as malnutrition, reduced immunity and 
anemia [35]. Anthelmintic drugs have been observed to have impressive infection cure 
rates anywhere from 76-98%, with most of these drugs having broad-spectrum 
anthelmintic effects [35]. These drugs function with extremely high efficacy while being 
relatively inexpensive in terms of drug cost [35]. Two main types of anthelmintics were 
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identified as hits in my high throughput screening: benzimidazoles (including 
albendazole, flubendazole, mebendazole and fenbendazole) and niclosamide (Appendix 
3). 
 In recent years, the repurposing of drugs for alternate uses than what was 
originally intended has become increasingly popular as investigators seek new treatment 
options for different human diseases. Interestingly, investigations into anthelmintics for 
the treatment of various cancers have proven highly promising. Flubendazole was 
observed to effectively enhance cytotoxicity in breast cancer cells [36], mebendazole was 
identified as a hit in a high throughput screen looking for compounds effective at 
controlling colon cancer cell line growth [37] and niclosamide has been found to 
effectively inhibit proliferation of human osteosarcoma cells as well as enzalutamide-
resistant prostate cancer cells [38, 39]. Additionally, anti-protozoals, which include 
anthelmintic compounds, have been found to efficaciously kill cancer subtypes enriched 
for stem-like properties [40]. These recent findings along with the results from my 
expanded screening all support old/existing microbicides being further explored for the 
potential repurposing as new cancer therapeutics to eradicate HNSCC cancer cells. 
 
6.2.3 Select HNSCC cell lines were less sensitive to 
chemotherapeutics 
 
 Following analysis of my preliminary drug screens, I observed that the HNSCC 
cell lines SCC-4, PCI6A and SCC-25 all appeared to be less sensitive overall to the 
majority of compounds included in my screens, with SCC-25 remaining relatively 
insensitive even with my confirmatory dose response curves (Appendix 2, Figure 9). 
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Review of the raw fluorescence data obtained for each of these cell lines found that they 
all had similar readings to the other HNSCC cell lines tested thus indicating comparable 
levels of cellular viability across all samples tested. 
 One possible explanation for this trend is that SCC-4 and SCC-25 were observed 
to have increased doubling times than most of the cell lines screened, which could 
account for certain compounds not appearing to be as effective while appearing highly 
potent in the remainder of HNSCC cell lines tested. An increased doubling time would 
infer that these cells are not going through as many rounds of the cell cycle, so 
compounds affecting regulation of the cell cycle or cytoskeleton formation during 
cellular division, which many of the top compounds do, may be less effective in such cell 
lines. Other explanations for this insensitivity could be that the cellular health of these 
specific HNSCC cell lines was poor and/or that these specific cell lines were 
contaminated, however, cell line identity was confirmed with STR profiling prior to 
screening and any bacterial contamination should have been obvious when screening as 
addition of alamarBlue would result in an extremely positive outlier for metabolic 
activity. 
 
6.2.4 Expanded screening identified compounds with preferential 
activity in HPV-positive or HPV-negative HNSCC cell lines 
 
 Based on what was previously known about HNSCC including the differing 
etiologies of tobacco exposure and infection with HPV [15], I hypothesized that because 
HPV-positive and HPV-negative HNSCC cell lines and xenografts are molecularly 
distinct, they would respond differentially to a subset of therapeutic agents identified in a 
57 
 
high throughput drug screen. Initially, I was forced to reject my null hypothesis since no 
hit compounds from my preliminary screening of 1,505 compounds, were found to be 
preferentially active in either HPV-positive or HPV-negative HNSCC cell lines. 
However, when I subsequently performed a drug screen using an expanded panel of 
1,825 drug compounds on a subset of HNSCC cell lines, I was able to identify 
compounds that affected HPV-positive or HPV-negative cells exclusively (Table 8). 
 
6.2.4.1 Hycanthone displayed preferential activity in HPV-positive 
HNSCC cell lines 
 
 Hycanthone was identified in my expanded high throughput screen as being 
preferentially active in HPV-positive HNSCC cell lines (Appendix 3). Since HPV-
positive patients have been found to have better overall survival than their HPV-negative 
counterparts, it is imperative that compounds targeting HPV-positive tumours specifically 
are identified to help treat these patients since they will likely have to live with the 
toxicities of their treatment. Hycanthone functions by intercalating into DNA and 
inhibiting RNA synthesis and it has been found to be a potential anti-neoplastic agent. 
Phase I clinical trials have been completed in advanced cancers [41], which are cancers 
that are unlikely to be cured as well as advanced metastatic cancers [42] and a phase II 
trial has been completed for hycanthone in advanced colorectal carcinoma [43]. One 
potential explanation for its preferential activity in HPV-positive HNSCC cell lines is that 
cells infected with HPV often depend on the expression and oncogenic function of HPV 
oncoproteins E6 and E7, which target p53 and pRb, respectively, for degradation [4, 15]. 
This dependency on expression of E6 and E7 for tumourigenesis may also depend on 
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increased rates of transcription, which could potentially explain why an inhibitor of RNA 
synthesis was found to display activity in these HPV-positive cells. To date, hycanthone 
has not been explored as a therapeutic option for HNSCC, thus opening up the possibility 
for further investigation into its cellular mechanism of action and differential activity in 
HPV-positive and HPV-negative HNSCC cells. 
 
6.2.4.2 Compounds with preferential activity in HPV-negative 
HNSCC cell lines 
 
 Conversely, 5 compounds were found to be hits in HPV-negative HNSCC cell 
lines exclusively (Table 8). Upon review of the literature, I found limited evidence 
examining the roles of 6-azauridine, an anti-viral agent, and primaquine diphosphate, an 
anti-parasitic, in cancer. However, these compounds, along with many other drugs that 
were identified as being extremely potent across all 6 cell lines in the expanded drug 
screen, were found to be anti-parasitics (including anthelmintics) as well as antibiotics 
(Appendix 3). A recent publication by Lamb and colleagues (2015) found that 
puromycin, along with other antibiotics targeting protein translation, could suppress 
cancer stem cells in culture and control the formation of tumourspheres [44]. 
Furthermore, others have observed that antibiotics targeting active sites of the ribosome 
directly as well as indirect inhibitors of protein synthesis have an extensive cytotoxic 
effect on breast cancer cells in vitro [40]. Cuyàs and colleagues (2015) concluded that 
cancer subtypes that are enriched with properties of stem cells (such as the ability to 
divide and renew themselves) exhibit an extreme sensitivity to antibiotics and anti-
protozoals targeting protein synthesis [40]. These findings could help provide an 
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explanation as to why many antibiotics (e.g. puromycin) and anti-protozoals (e.g. 
albendazole) were observed to be active in my panel of HNSCC cell lines (Table 8, 
Appendix 3). 
 
6.2.5 NSC146109 hydrochloride effectively inhibited HNSCC cell 
line growth in vitro 
 
 NSC146109 hydrochloride was identified as one of the top 10 most active 
compounds in my high throughput drug screen (Appendix 2). NSC146109 hydrochloride 
is an activator of p53 that has been found to activate p53 transcription, increase levels of 
p53 in tumour cells and protect p53 from E3 ubiquitin-protein ligase (Mdm2)-mediated 
degradation [33]. To ensure that this compound was controlling HNSCC cell line 
proliferation in vitro by this cellular mechanism, I attempted to look at TP53 transcript 
levels using quantitative RT-PCR. Unfortunately, TP53 transcript levels were too low to 
be accurately detected and compared (Figure 11). In addition, a suitable positive control 
was not obtained and I was therefore unable to normalize the untreated samples in order 
to gain an understanding of baseline TP53 transcript levels within HNSCC tumour cells.  
 Currently, I am attempting to use normal, non-cancerous human cell lines as a 
positive control to redo the RT-PCR experiment to see if I can get a better measure of 
TP53 levels in untreated cell lines and subsequently, using the now normalized untreated 
TP53 transcript levels to compare to NSC146109 hydrochloride-treated cells with the 
expectation of TP53 transcript levels increasing. 
Next, I plan to investigate p53 levels at the protein level using Western blot 
analysis where I will compare levels of p53 protein in treated cells versus untreated cells. 
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Examination of p53 protein enables conclusions to be drawn regarding levels of p53 at 
the functional level since this is the molecule that acts as an essential tumour suppressor 
within the cell. Looking exclusively at TP53 transcript levels is not a direct measurement 
of levels of p53 protein, which is why investigation into p53 protein levels upon 
treatment with NSC146109 hydrochloride is essential to confirm its mechanism of action 
within the cell. 
Finally, I will examine cellular levels of p21 in response to reactivation of p53 as 
p21 is a well-documented downstream functional target of p53 activation [45, 46]. P21 is 
a potent and universal inhibitor of cyclin-dependent kinases and functions as a regulator 
of cell cycle progression [47]. Increases in p53 have been found to result in increased 
levels of p21, which inhibits the proliferation of mammalian cells [45, 47]. Since 
NSC146109 hydrochloride functions to reactivate p53 within the cell by protecting it 
from Mdm2-mediated degradation, I expect increased levels of p53 protein within the 
cell along with increased levels of its downstream target p21, upon treatment of HNSCC 
cells with this compound.  
 Testing of NSC146109 hydrochloride using in vivo cell line xenografts was 
intended, however, there were issues with the solubility of the compound when 
attempting to resuspend it for intraperitoneal dose delivery in mice. This issue is currently 
being examined where I am pursuing different reagents (e.g. DMSO, ethanol) in varying 
concentrations in an attempt to solubilize NSC146109 hydrochloride at concentrations 
suitable for in vivo mouse xenograft experiments.  
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6.2.5.1 TP53 and Cancer 
 
 TP53, which encodes p53 protein, is one of the most well known tumour 
suppressor genes in cancer and is mutated or lost in approximately 50% of all human 
malignancies [48]. As the “guardian of the genome”, p53 regulates cell cycle progression 
by initiating G1-arrest in response to DNA damage and loss of functional p53 results in 
unregulated cellular division, or cancer cell formation [48]. A recent genomic 
characterization of HNSCC reported the frequency of p53 mutations and/or deletions at 
84% in HPV-negative HNSCC tumours and 3% HPV-positive tumours [20]. 
Interestingly, disruptive mutant p53 has been found to be correlated with decreased 
recurrence-free survival as well as a valuable predictive biomarker in the development of 
local recurrences compared to patients with non-disruptive mutations or wild-type TP53 
[49, 50, 51].  
 Investigations into small molecule activators of p53 have found that these 
compounds can induce apoptosis and enhance cytotoxicity in HNSCC cell lines [52]. 
Compounds such as nutlin-3, RITA, CP-31398, PRIMA-1 and Minnelide™ have all been 
shown to successfully control HNSCC cell line proliferation in vitro against HNSCC cell 
lines through reactivation of p53 [52, 53]. Although these compounds have proven 
successful in vitro and in select preclinical models of HNSCC [52], there are currently no 
clinical trials investigating such compounds in head and neck cancer, thus providing a 
potential opportunity to explore this target as a treatment for patients suffering from 
HNSCC. 
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6.2.6 ER27319 maleate suppressed HNSCC cell line proliferation 
in vitro and controlled tumour growth in vivo 
 
 In addition to NSC146109 hydrochloride, the compound ER27319 maleate was 
also selected for preclinical development due to its high activity in HNSCC cell lines. 
ER27319 maleate has been found to inhibit phosphorylation of spleen tyrosine kinase 
(Syk) within the cell [34, 54]. In order to verify that ER27319 maleate is controlling 
HNSCC cell line proliferation through inhibition of Syk phosphorylation, both 
endogenous and phosphorylated Syk were examined in both treated and untreated 
HNSCC cells. Syk has 3 different sites that can undergo phosphorylation (Tyr323; 
Tyr525/526), all of which may be affected upon treatment with ER27319 maleate, so it 
was important to attempt to look at all of these sites in my studies. Although observation 
of endogenous Syk using Western blot analysis proved successful, I was unable to 
effectively visualize phosphorylated Syk, particularly in the context of untreated HNSCC 
cells and thus was unable to make any concrete conclusions regarding ER27319 maleate 
inhibiting Syk phosphorylation in vitro (Figure 12).   
 Currently, I am attempting to boost universal cellular phosphorylation by growing 
cells in serum-free media, which induces a stressed state and increases global 
phosphorylation within the cell. By increasing cellular phosphorylation, I hope to elevate 
phosphorylated Syk levels to levels that can be effectively visualized by Western Blow 
analysis. Once phosphorylated Syk can be efficiently visualized through universal 
amplification of cellular phosphorylation, comparisons between ER27319 maleate-treated 
cells and untreated cells can be made to ensure that ER27319 maleate is in fact 
controlling HNSCC cell line growth by inhibiting phosphorylation of Syk. 
63 
 
 Additionally, future studies with this compound will involve examination of both 
endogenous and phosphorylated Syk levels across my entire panel of HNSCC cell lines. 
Gaining a better understanding of total Syk and phosphorylated Syk levels in all 28 
HNSCC cell lines will enable appropriate cell line selection for future experiments when 
attempting to examine changes in Syk phosphorylation (i.e. examination of an HNSCC 
cell line with increased levels of phosphorylated Syk in untreated cells may allow for an 
visible and ideally indisputable inhibitory effect on Syk phosphorylation to be observed 
upon addition of ER27319 maleate). 
 With the knowledge that ER27319 maleate could effectively control HNSCC cell 
line proliferation in vitro, I wanted to examine the effect this compound had in an in vivo 
cancer model using cell line xenografts. Mice treated with ER27319 maleate (40 mg/kg) 
had significantly reduced tumour growth as compared to untreated control tumours 
(Table 9, Figure 13). In addition, the compound was extremely well tolerated amongst all 
animals tested as evidenced by subjective observation. Future experiments will involve 
treating cell line xenografts with an increased dose of ER27319 maleate (70 mg/kg), 
which was also found to be well tolerated, to see if I can further reduce tumour growth or 
even stop tumour growth completely. This preliminary data helps support my findings of 
ER27319 maleate demonstrating high activity both in vitro and in vivo in HNSCC cell 
lines and opens up the possibility of further preclinical modeling of this compound 
towards its development for the treatment of HNSCC.  
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6.2.6.1 Spleen Tyrosine Kinase 
 
Spleen tyrosine kinase (commonly referred to as Syk) is a member of the Syk 
family of tyrosine kinases that has historically been associated with transmitting cellular 
immune signals within B cells in the initiation of the immune response [55]. More 
recently, Syk has been recognized as functioning as a promoter of cell survival in a 
variety of different cell types [55]. Interestingly, Syk has also been found to promote cell 
motility and progression in vitro in HNSCC cell lines [56]. Furthermore, an investigation 
by Du and colleagues (2012) observed that Syk levels are elevated in nasopharyngeal 
cancer and this was found to be correlated with poor patient prognosis thus presenting the 
opportunity for a new prognostic biomarker [57]. 
 ER27319 maleate was one of the top drugs uncovered in my high throughput drug 
screening that displayed extremely high activity across all HNSCC cell lines tested. This 
evidence of its ability to efficiently control HNSCC cell line proliferation both in vitro 
and  in vivo, combined with its newly associated role in epithelial cell motility and cell 
cycle progression, presents the possibility of a new and promising therapeutic target in 
HNSCC. 
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6.3 Limitations to the Study 
 
 One of the major limitations of this study was the use of cell lines as a model of 
HNSCC. Cell lines grow in a two dimensional monolayer in culture and are thus not the 
best representation of a three dimensional patient tumour. In addition, due to their two 
dimensional growth, cell lines are unable to replicate the tumour microenvironment, a 
series of complex interactions that facilitate tumorigenesis including stromal interactions, 
tumour vascularisation, various signaling molecules as well as the interactions with the 
extracellular matrix. This lack of accurate tumour replication, including the tumour 
microenvironment, does not enable us to assess drug delivery as well as drug metabolism 
in the context of an actual tumour environment.  
 Another major limitation of my study was the number of drugs tested. In my high 
throughput drug screen, libraries of 1,505 and 1,825 drug compounds were screened 
against HNSCC cell lines. Although this screen is the largest for the number of drug 
compounds performed to date, for HNSCC specifically, there is still the possibility that 
many active compounds may have been missed due to their lack of presence in my 
screen. Although not completely comprehensive, my drug screens were extremely 
extensive when it comes to drug testing in HNSCC. Additionally, I was able to 
successfully identify many novel agents that warrant further investigation for the 
treatment of HNSCC. 
 An additional limitation was the readout assay used for my high throughput drug 
screening. The alamarBlue viability assay, which provides a readout of cellular metabolic 
activity, enabled me to perform high throughput drug screening on a large-scale at a 
relatively low cost. Unfortunately, this assay does not give us any specific information on 
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whether or not cells stop proliferating due to apoptosis or senescence, for example. 
Additional assays could have been used as readouts for my screening such as caspase 
assays, which look at apoptosis as well as β-galactosidase assays, which examine cellular 
senescence, however, the reagents for these assays tend to be quite expensive. 
Examination of the effects of the 23 drugs selected for hit confirmation using additional 
readouts such as cellular senescence and apoptosis, as mentioned above, may provide 
further insight into the mechanisms of actions of these compounds as well as be more 
cost effective as compared to large-scale screening with these specific assays. 
 Finally, a major limitation of this study was that my large-scale drug screening 
was only performed at a single drug concentration. Screening at a single dose was 
necessary in order to test as many cell lines against the number of drugs that I screened; 
however, it is very possible that some highly active compounds were not identified. Some 
drugs may require increased doses for an anti-proliferative effect to be observed so it is 
likely that some potentially potent compounds were missed due to the selected screening 
dose not being in the optimal activity range for such compounds. 
 
6.4 Future Directions 
 
 Further investigation is required for elucidation of the mechanisms of actions for 
the top drug compounds identified in my high throughput screening. In addition, 
combinational drug therapies will be explored using both data from my drug screening as 
well as relevant background information regarding drug and cellular targets from the 
literature. Combinational drug screening is important to overcome potential issues of 
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drug resistance as well as to identify possible synergistic drug effects. In addition, I plan 
on testing top drug hits in patient-derived xenografts (PDX) models. PDX will enable me 
to validate my in vitro screening and in vivo cell line xenograft model using actual patient 
tumours. PDX have been found to maintain the genomic alterations of the original patient 
tumour and have been found to be accurate in predicting patient response [58, 59].  
 The long-term goal of this project is to pair my drug sensitivity data to HNSCC 
cell line genomic data in order to identify biomarkers of drug sensitivity and/or 
resistance. The automated nature of this project has enabled a large number of HNSCC 
cell lines to be screened against extensive chemical panels, which is crucial for providing 
the statistical power required to make correlations between drug response and genetics. 
There is currently a lack of reliable predictive biomarkers for treatment response in 
HNSCC. One reason for this is due to the heterogeneity of HNSCC tumours, which 
makes it difficult to identify patient cohorts that can predict responses to particular 
therapeutics. In an effort to overcome this issue, it is essential that a large number of drug 
compounds are screened so active compounds can be identified. As well, it is vital that an 
extensive number of HNSCC cell lines are screened against these large chemical libraries 
so conclusions regarding markers of drug sensitivity and/or resistance can be accurately 
made. 
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7 CONCLUSIONS 
 
 High throughput drug screening identified therapeutic agents that are highly 
active in a panel of HNSCC cell lines. My screen of 1,505 compounds, along with an 
expanded screen of 1,825 drugs against a subset of HNSCC cell lines, identified both 
known and novel targets in HNSCC. Additionally, 23 compounds were confirmed as 
being highly active in HNSCC cell lines in vitro through the generation of 10-point dose 
response curves. One of these compounds, ER27319 maleate, an inhibitor of Syk 
phosphorylation, was found to reduce tumour growth in vivo in a cell line xenograft 
model.  
 Further investigations need to be performed to systematically and 
comprehensively characterize each compound as well as its ability to control HNSCC cell 
line and tumour growth in vitro and in vivo, respectively. In addition, my drug sensitivity 
data will eventually be paired with cell line genomic analyses to facilitate the 
identification of genetic biomarkers of drug response. Once combined, this strategy of 
high throughput drug screening paired with genomic analysis has the potential to not only 
identify novel agents to improve outcomes in HNSCC, but also identify ideal patient 
populations to offer each drug to, thus delivering the goal of precision medicine to 
HNSCC. 
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APPENDICES 
 
 
Appendix 1. STR profiles of HNSCC cell lines used for screening. 
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HMS001 X,Y 11,11 8,8 9,12 11,12 12,12 6,6 8,8 17,17 15,20 13,14 28,29 21,21 15,15 13,15 24,24 
UM-SCC47 X,Y 11,13 8,11 8,13 11,12 11,11 7,9.3 10,11 18,18 18,18 14,15 29,30 25,25 15,15 15,15 25,25 
UPCI:SCC090 X,Y 11,12 11,11 12,13 11,12 9,10 7,7 8,8 17,17 14,18 12,13 39,31 22,22 14,14 12,12 20,20 
UPCI:SCC154 X,Y 10,12 9,12 13,13 11,12 9,10 7,7 8,9 17,17 15,15 15.2,16 28,29 25,25 16,16 12,12 20,24 
Cal27 X,X 10,12 10,11 11,12 11,12 10,10 6,9.3 8,8 14,17 13,13 14,15.2 28,29 23,24 16,16 13,15 25,25 
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SCC-9 X,Y 11,11 9,9 10,11 12,12 8,8 8,9 9,11 17,17 12,14 12,14 28,28 19,21 15,15 13,13 20,25 
SCC-15 X,Y 10,13 9,14 12,15 12,12 10,11 9,9.3 8,8 15,17 16,16 12,15 30,30 16,23 16,16 10,13 24,24 
SCC-25 X,X 10,10 13,13 11,12 12,12 12,12 8,8 8,12 17,19 16,16 13,14 30,30 17,19 17,17 13,13 20,24 
Cal33 X,Y 11,12 8,13 11,11 11,12 8,10 9,9.3 8,8 17,17 14,14 14,15.2 29,30 20,25 17,17 13,13 21,22 
JHU006 X,Y 10,10 11,11 12,12 12,12 9,10 6,6 8,8 14,16 16,16 14,14.2 31,31 17,25 13,13 13,14 19,19 
JHU011 X,X 10,12 12,12 9,14 9,12 11,11 6,9 8,9 16,17 13,15 13,14 31,31 17,26 18,18 13,13 23,23 
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PCI6A X,X 12,12 9,11 11,11 11,12 8,12 6,6 11,11 15,18 12,17 15,16.2 31.2,31.2 17,24 18,18 14,14 23,23 
PCI6B X,Y 10,11 10,11 12,13 12,12 12,13 6,7 8,9 16,18 16,16 12,14 32.2,32.2 23,24 18,18 13,14 20,20 
PCI13 X,X 10,14 10,11 11,11 11,14 11,12 9,9.3 6,8 13,17 16,16 13,15.2 29,30 24,24 14,14 12,13 22,22 
PCI30 X,Y 10,10 13,13 12,13 11,11 10,12 6,6 10,11 14,17 12,15 12,12 30,32.2 18,18 15,15 13,15 21,21 
RF15A X,X 10,12 12,12 9,9 10,12 10,11 6,6 8,11 17,17 16,18 13,14 29,29 20,23 16,16 14,14 22,22 
RF15B X,Y 11,11 11,11 11,11 11,11 11,11 6,6 8,8 18,18 14,14 14,15.2 28,28 20,25 16,16 14,14 23,23 
RF22A X,X 10,10 8,12 9,11 12,12 8,9 6,6 8,11 15,18 18,18 14,15 28,28 17,20 16,16 11,13 22,24 
RF22B X,X 10,12 8,11,12 9,12,13 10,12,13 9-12 6,6 8,11 15-18 16,18 12,13,14 27,29 20,22,23 16,18 
13-
16 
18,22 
RF37A X,X 11,11 10,13,14 11,14 11,11 7,10 7,9.3 8,11 16,17 13,13 15,16 30,32.2 24,24 17,17 11,13 21,21 
RF37B X,X 10,12 12,12 9,9 10,12 10,11 6,6 8,11 17,17 16,18 13,14 29,29 20,23 16,16 14,14 22,22 
BICR56 X,X 12,12 12,12 11,11 11,12 8,12 9,9.3 8,9 15,16 14,17 14,15 28,29 24,26 14,14 11,13 21,21 
PE/CA-PJ49 X,X 11,12 8,11 11,11 8,12 8,9 6,10 8,8 16,19 24,24 14,14 32,32 17,18 16,16 10,11 20,20 
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Appendix 2. Drug hits identified by high throughput drug screening in HNSCC cell 
lines. 
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GW 843682X                         
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KF 38789                         
  
           
          
Cytochalasin D                         
  
          
 
          
S-Trityl-L-
cysteine 
                        
  
        
   
          
Rottlerin                         
  
           
          
SB 225002                         
  
          
 
          
Y-26763                         
  
           
          
(Â±)-threo-3-
Methylglutamic 
acid 
                        
  
        
  
 
          
Tacrine 
hydrochloride 
                        
  
        
   
          
CMPD-1                         
  
           
          
Scopolamine 
hydrobromide 
                        
  
        
   
          
Y-27152                         
  
           
          
Ki 8751                         
  
          
 
          
OLDA                         
  
          
 
          
DHBP 
dibromide 
                        
  
        
   
          
NSC 3852                         
  
          
 
          
BADGE                         
  
           
          
D-AP7                         
  
          
 
          
PALDA                         
  
          
 
          
 
Reduction in cellular proliferation: red, 90-100%; orange, 80-90%; yellow, 70-80%; light green, 60-70%; 
dark green, 50-60%; light blue, 40-50%; dark blue, 30-40%, purple, 20-30%; grey, <20%. 
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Appendix 3. Drug hits (in red) from expanded drug panel screening. 
Library 
 
Drug 
 
Target 
   F
a
D
u
 
  
C
a
l2
7
 
  
D
5
6
2
 
  
9
3
-V
U
-1
4
7
T
 
  
U
M
-S
C
C
4
7
 
  
H
M
S
-0
0
1
 
NIH Homoharringtonine Protein synthesis             
Prestwick Piperlongumine Anti-cancer             
Prestwick Mycophenolic acid Anti-cancer             
NIH/Prestwick Daunorubicin Hydrochloride DNA/RNA synthesis             
NIH Mitoxantrone DNA synthesis             
NIH Epirubicin Hydrochloride DNA/RNA synthesis             
NIH 2-chloro-2'-deoxyadenosine DNA synthesis             
NIH Podofilox Antimitotic             
Prestwick Hycanthone RNA/DNA synthesis             
NIH/Prestwick Albendazole Anthelmintic             
NIH Flubendazole Anthelmintic             
NIH/Prestwick Mebendazole Anthelmintic             
Prestwick Parbendazole Anthelmintic             
Prestwick Niclosamide Anthelmintic             
Prestwick Fenbendazole Anthelmintic             
Prestwick Oxantel pamoate Anthelmintic             
NIH Vincristine Sulfate Microtubules             
NIH Vindesine Sulfate Microtubules             
NIH Vinorelbine Bitatrate Microtubules             
Prestwick Colchicine Microtubules             
Prestwick Nocodazole Microtubules             
NIH Docetaxel Microtubules             
NIH Irinotecan HCl (trihydrate) Topoisomerase I             
NIH Idarubicin HCl Topoisomerase II             
NIH Doxorubicin Hydrochloride Topoisomerase II             
NIH Topotecan HCL Topoisomerase             
Prestwick Podophyllotoxin Topoisomerase             
NIH Etoposide Topoisomerase             
Prestwick Ellipticine Topoisomerase             
Prestwick Etoposide Topoisomerase             
NIH Dactinomycin Antibiotic             
NIH Telithromycin Antibiotic             
Prestwick Puromycin dihydrochloride Antibiotic             
Prestwick Metampicillin sodium salt Antibiotic             
NIH/Prestwick Metronidazole Antibiotic             
Prestwick Thonzonium bromide Antibiotic             
NIH Cephalexin monohydrate Antibiotic             
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Prestwick Thiostrepton Antibiotic             
Prestwick Benzylpenicillin sodium Antibiotic             
NIH Triptolide NF-κB             
Prestwick Parthenolide NF-κB             
NIH Clofazimine Anti-inflammatory             
NIH Valdecoxib Anti-inflammatory             
NIH Diphenylcyclopropenone Topical Immunotherapy             
NIH Hydrocortisone Immunosuppressant             
NIH Dipyridamole Thrombus formation             
NIH Raclopride Dopamine D2/D3 receptor             
Prestwick Thiethylperazine malate Dopamine antagonist             
Prestwick 
Apomorphine hydrochloride 
hemihydrate 
Dopamine agonist 
            
NIH Rythmol Antiarrhythmic             
Prestwick Ajmaline Antiarrhythmic             
Prestwick Clofilium tosylate Antiarrhythmic             
NIH Mosapride Citrate 5-HT4 agonist             
NIH 5-Nonyloxytryptamine 5-HT1 eceptor             
NIH Tegaserod Maleate 5-HT4 agonist             
Prestwick Scoulerine 5-HT receptor             
Prestwick Chloropyramine hydrochloride Antihistamine             
Prestwick Brompheniramine maleate Antihistamine             
Prestwick Tranylcypromine hydrochloride Histone demethylation             
NIH Azacitidine DNA methylation             
NIH Cogentin Mesylate Acetylcholine levels             
Prestwick Gallamine Triethiodide Acetylcholine levels             
NIH Cerivastatin Na Statin             
NIH Itavastatin Ca Statin             
NIH Methyltestosterone Oral steroid             
Prestwick Fluorometholone Corticosteroid             
Prestwick Methyldopate hydrochloride Anti-hypertensive             
NIH Fenoldopam Mesylate Anti-hypertensive             
NIH LY 171883 PPARα/PPARγ             
NIH Rosigltazone HCl PPARγ             
NIH Valaciclovir Hydrochloride Anti-viral             
NIH 6-Azauridine Anti-viral             
NIH Fluphenazine HYDROCHLORIDE Anti-psychotic             
Prestwick Thioridazine hydrochloride Anti-psychotic             
Prestwick Benzethonium chloride Anti-microbial             
Prestwick Ciclopirox ethanolamine Anti-fungal             
NIH/Prestwick Itraconazole Anti-fungal             
Prestwick Primaquine diphosphate Anti-parasitic             
Prestwick Methimazole Anti-thyroid             
Prestwick Fenoterol hydrobromide Adrenergic agonist             
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Prestwick Proxyphylline Xanthine derivative             
Prestwick Strophantine octahydrate Cardiac glycosides             
NIH/Prestwick Tomelukast Antiasthmatic             
NIH Tiagabine HCl Anti-convulsive             
NIH Rosiglitazone Maleate Anti-diabetic             
NIH Ranitidine hydrochloride Histamine H2 receptor             
NIH Toremifene Citrate Estrogen receptor             
NIH Tetraethylthiuram Disulfide Alcohol dehydrogenase             
Prestwick Disulfiram Acetaldehyde dehydrogenase             
NIH Procaine hydrochloride Na+ channel             
NIH Pyrimethamine MATE transporters             
Prestwick Omeprazole Proton Pump Inhibitor             
Prestwick Quinacrine dihydrochloride dihydrate MAO-A/B inhibitor             
Prestwick Letrozole Aromatase Inhibitor             
Prestwick Bucladesine sodium salt Phosphodiesterase inhibitor             
Prestwick Proscillaridin A Na+/K+ ATPase             
NIH/Prestwick Moxisylyte hydrochloride α-blocker             
NIH Bifemelane Antidepressant (MAO)             
NIH Hydrochlorothiazide Diuretic             
NIH 
3-hydroxy-1,2-dimethyl-4(1H)-
pyridone 
Iron chelator 
            
Prestwick Chelidonine monohydrate (+) Unknown             
NIH 1H-CAS Unknown             
Prestwick Methotrimeprazine maleate salt Unknown             
Prestwick Chrysene-1,4-quinone Unknown             
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Appendix 4. Ethics approval for in vivo cell line xenograft model. 
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